![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
FP Guengerich, D Muller-Enoch and IA Blair
The anti-arrhythmic quinidine has been reported to be a competitive inhibitor of the catalytic activities of human liver P-450DB, including sparteine delta 2-oxidation and bufuralol 1'-hydroxylation, and we confirmed the observation that submicromolar concentrations are strongly inhibitory. Human liver microsomes oxidize quinidine to the 3- hydroxy (Km 4 microM) and N-oxide (Km 33 microM) products, consonant with in vivo observations. Both bufuralol and sparteine inhibited microsomal quinidine 3-hydroxylation. Liver microsomes prepared from DA strain rats showed a relative deficiency in quinidine 3-hydroxylase activity in females compared to males. These observations might suggest that quinidine oxidation is catalyzed by the same P-450 forms that oxidize debrisoquine, bufuralol, and sparteine; i.e., rat P-450UT-H and P-450DB. However, neither of these two purified enzymes catalyzed quinidine 3-hydroxylation, and anti-P-450UT-H, which strongly inhibits human liver microsomal bufuralol 1'-hydroxylation, did not substantially inhibit quinidine 3-hydroxylation or N-oxygenation. P- 450MP, the human S-mephenytoin 4-hydroxylase, also does not appear to oxidize quinidine but P-450NF, the human nifedipine oxidase, does. Anti- P-450NF inhibited greater than 95% of the 3-hydroxylation and greater than 85% of the N-oxygenation of quinidine in several microsomal samples. Quinidine inhibited microsomal nifedipine oxidation and, in a series of human liver samples, rates of nifedipine oxidation were correlated with rates of quinidine oxidation. Thus, quinidine oxidation appears to be catalyzed primarily by P-450NF and not by P-450DB. Quinidine binds 2 orders of magnitude more tightly to P-450DB, which does not oxidize it, than to P-450NF, the major enzyme involved in its oxidation. The substrate specificity of human P-450NF is discussed further in terms of its regioselective oxidations of complex molecules including quinidine, aldrin, benzphetamine, cortisol, testosterone and androstenedione, estradiol, and several 2,6-dimethyl-1,4- dihydropyridines.
This article has been cited by other articles:
|
|
 |
|
  L. Perrin, C. Aninat, V. Hamon, Y. Hayashi, C. Abadie, B. Heyd, F. Andre, and M. Delaforge Metabolism of Phenylahistin Enantiomers by Cytochromes P450: A Possible Explanation for Their Different Cytotoxicity Drug Metab. Dispos., November 1, 2008; 36(11): 2381 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. McLaughlin, M. J. I. Paine, C. A. Kemp, J.-D. Marechal, J. U. Flanagan, C. J. Ward, M. J. Sutcliffe, G. C. K. Roberts, and C. R. Wolf Why Is Quinidine an Inhibitor of Cytochrome P450 2D6?: THE ROLE OF KEY ACTIVE-SITE RESIDUES IN QUINIDINE BINDING J. Biol. Chem., November 18, 2005; 280(46): 38617 - 38624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Yu, K. Fukamachi, K. W. Krausz, C. Cheung, and F. J. Gonzalez Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis Endocrinology, July 1, 2005; 146(7): 2911 - 2919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Reid, D. L. Walker, J. K. Miller, L. M. Benson, A. J. Tomlinson, S. Naylor, A. L. Blajeski, P. M. LoRusso, and M. M. Ames The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes Clin. Cancer Res., February 15, 2004; 10(4): 1471 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Wynalda, J. M. Hutzler, M. D. Koets, T. Podoll, and L. C. Wienkers IN VITRO METABOLISM OF CLINDAMYCIN IN HUMAN LIVER AND INTESTINAL MICROSOMES Drug Metab. Dispos., July 1, 2003; 31(7): 878 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Wienkers and M. A. Wynalda Multiple Cytochrome P450 Enzymes Responsible for the Oxidative Metabolism of the Substituted (S)-3-Phenylpiperidine, (S,S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine Hydrochloride, in Human Liver Microsomes Drug Metab. Dispos., December 1, 2002; 30(12): 1372 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Masubuchi, A. Ose, and T. Horie Diclofenac-Induced Inactivation of CYP3A4 and Its Stimulation by Quinidine Drug Metab. Dispos., October 1, 2002; 30(10): 1143 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Guengerich, G. P. Miller, I. H. Hanna, H. Sato, and M. V. Martin Oxidation of Methoxyphenethylamines by Cytochrome P450 2D6. ANALYSIS OF RATE-LIMITING STEPS J. Biol. Chem., September 6, 2002; 277(37): 33711 - 33719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ngui, Q. Chen, M. Shou, R. W. Wang, R. A. Stearns, T. A. Baillie, and W. Tang In Vitro Stimulation of Warfarin Metabolism by Quinidine: Increases in the Formation of 4'- and 10-Hydroxywarfarin Drug Metab. Dispos., June 1, 2001; 29(6): 877 - 886. [Abstract] [Full Text]
|
|
|
|
|
|
M. He, A. E. Rettie, J. Neal, and W. F. Trager Metabolism of Sulfinpyrazone Sulfide and Sulfinpyrazone by Human Liver Microsomes and cDNA-Expressed Cytochrome P450s Drug Metab. Dispos., April 13, 2001; 29(5): 701 - 711. [Abstract] [Full Text]
|
|
|
|
|
|
J. Easterbrook, C. Lu, Y. Sakai, and A. P. Li Effects of Organic Solvents on the Activities of Cytochrome P450 Isoforms, UDP-Dependent Glucuronyl Transferase, and Phenol Sulfotransferase in Human Hepatocytes Drug Metab. Dispos., February 1, 2001; 29(2): 141 - 144. [Abstract] [Full Text]
|
|
|
|
|
|
K. Ohyama, M. Nakajima, S. Nakamura, N. Shimada, H. Yamazaki, and T. Yokoi A Significant Role of Human Cytochrome P450 2C8 in Amiodarone N-Deethylation: An Approach to Predict the Contribution with Relative Activity Factor Drug Metab. Dispos., November 1, 2000; 28(11): 1303 - 1310. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Wynalda, M. J. Hauer, and L. C. Wienkers Oxidation of the Novel Oxazolidinone Antibiotic Linezolid in Human Liver Microsomes Drug Metab. Dispos., September 1, 2000; 28(9): 1014 - 1017. [Abstract] [Full Text]
|
|
|
|
|
|
R. S. Obach Metabolism of Ezlopitant, a Nonpeptidic Substance P Receptor Antagonist, in Liver Microsomes: Enzyme Kinetics, Cytochrome P450 Isoform Identity, and In Vitro-In Vivo Correlation Drug Metab. Dispos., September 1, 2000; 28(9): 1069 - 1076. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Tang, R. A. Stearns, G. Y. Kwei, S. A. Iliff, R. R. Miller, M. A. Egan, N. X. Yu, D. C. Dean, S. Kumar, M. Shou, et al. Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1068 - 1074. [Abstract] [Full Text]
|
|
|
|
|
|
L. C. Wienkers, C. Allievi, M. J. Hauer, and M. A. Wynalda Cytochrome P-450-Mediated Metabolism of the Individual Enantiomers of the Antidepressant Agent Reboxetine in Human Liver Microsomes Drug Metab. Dispos., November 1, 1999; 27(11): 1334 - 1340. [Abstract] [Full Text]
|
|
|
|
|
|
S. K. Paulson, L. Engel, B. Reitz, S. Bolten, E. G. Burton, T. J. Maziasz, B. Yan, and G. L. Schoenhard Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib Drug Metab. Dispos., October 1, 1999; 27(10): 1133 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ekins, G. Bravi, J. H. Wikel, and S. A. Wrighton Three-Dimensional-Quantitative Structure Activity Relationship Analysis of Cytochrome P-450 3A4 Substrates J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 424 - 433. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, M. Nakajima, K. Oshima, N. Shimada, T. Yokoi, and K. Chiba Involvement of CYP2E1 as A Low-Affinity Enzyme in Phenacetin O-Deethylation in Human Liver Microsomes Drug Metab. Dispos., August 1, 1999; 27(8): 860 - 865. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, T. Ishizuka, N. Shimada, Y. Yoshimura, K. Kamijima, and K. Chiba Short Communication: Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro Drug Metab. Dispos., July 1, 1999; 27(7): 763 - 766. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao, E. Koyama, and T. Ishizaki An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes Drug Metab. Dispos., July 1, 1999; 27(7): 776 - 785. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ludwig, J. Schmid, K. Beschke, and T. Ebner Activation of Human Cytochrome P-450 3A4-Catalyzed Meloxicam 5'-Methylhydroxylation by Quinidine and Hydroquinidine In Vitro J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
M. F. Fromm, D. Darbar, S. Dell'Orto, and D. M. Roden Modulation of Effect of Dietary Salt on Prehepatic First-Pass Metabolism: Effects of beta -Blockade and Intravenous Salt Loading J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 253 - 258. [Abstract] [Full Text]
|
|
|
|
|
|
T. L. Nielsen, B. B. Rasmussen, J.-P. Flinois, P. Beaune, and K. Brøsen In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine Is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 31 - 37. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Kiriyama, T. Nishiura, H. Yamaji, and K. Takada Metabolic Characterization of a Tripeptide Human Immunodeficiency Virus Type 1 Protease Inhibitor, KNI-272, in Rat Liver Microsomes Antimicrob. Agents Chemother., March 1, 1999; 43(3): 549 - 556. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kawashima, K. Hosoi, T. Naruke, T. Shiba, M. Kitamura, and T. Watabe Aldehyde Oxidase-Dependent Marked Species Difference in Hepatic Metabolism of the Sedative-Hypnotic, Zaleplon, Between Monkeys and Rats Drug Metab. Dispos., March 1, 1999; 27(3): 422 - 428. [Abstract] [Full Text]
|
|
|
|
|
|
S. Kudo, H. Okumura, G. Miyamoto, and T. Ishizaki Cytochrome P-450 Isoforms Involved in Carboxylic Acid Ester Cleavage of Hantzsch Pyridine Ester of Pranidipine Drug Metab. Dispos., February 1, 1999; 27(2): 303 - 308. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Darbar, M. F. Fromm, S. Dell'Orto, R. B. Kim, H. K. Kroemer, M. Eichelbaum, and D. M. Roden Modulation by Dietary Salt of Verapamil Disposition in Humans Circulation, December 15, 1998; 98(24): 2702 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Jones, R. Hyland, M. Ackland, C. A. Tyman, and D. A. Smith Interaction of Terfenadine and Its Primary Metabolites with Cytochrome P450 2D6 Drug Metab. Dispos., September 1, 1998; 26(9): 875 - 882. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Lillibridge, B. H. Liang, B. M. Kerr, S. Webber, B. Quart, B. V. Shetty, and C. A. Lee Characterization of the Selectivity and Mechanism of Human Cytochrome P450 Inhibition by the Human Immunodeficiency Virus-Protease Inhibitor Nelfinavir Mesylate Drug Metab. Dispos., July 1, 1998; 26(7): 609 - 616. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Voorman, S. M. Maio, M. J. Hauer, P. E. Sanders, N. A. Payne, and M. J. Ackland Metabolism of Delavirdine, a Human Immunodeficiency Virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A Drug Metab. Dispos., July 1, 1998; 26(7): 631 - 639. [Abstract] [Full Text]
|
|
|
|
|
|
H. Postlind, A. Danielson, A. Lindgren, and S. H. G. Andersson Tolterodine, a New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes Drug Metab. Dispos., April 1, 1998; 26(4): 289 - 293. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Grace, A. J. Aguilar, K. M. Trotman, and T. G. Brewer Metabolism of beta -Arteether to Dihydroqinghaosu by Human Liver Microsomes and Recombinant Cytochrome P450 Drug Metab. Dispos., April 1, 1998; 26(4): 313 - 317. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Sarver, K. A. Bachmann, D. Zhu, and W. A. Klis Ethosuximide is Primarily Metabolized by CYP3A when Incubated with Isolated Rat Liver Microsomes Drug Metab. Dispos., January 1, 1998; 26(1): 78 - 82. [Abstract] [Full Text]
|
|
|
|
|
|
S. H. Lee and J. T. Slattery Cytochrome P450 Isozymes Involved in Lisofylline Metabolism to Pentoxifylline in Human Liver Microsomes Drug Metab. Dispos., December 1, 1997; 25(12): 1354 - 1358. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao and T. Ishizaki The In Vitro Hepatic Metabolism of Quinine in Mice, Rats and Dogs: Comparison with Human Liver Microsomes J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1168 - 1176. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. H. Lin and A. Y. H. Lu Role of Pharmacokinetics and Metabolism in Drug Discovery and Development Pharmacol. Rev., December 1, 1997; 49(4): 403 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Wynalda and L. C. Wienkers Assessment of Potential Interactions Between Dopamine Receptor Agonists and Various Human Cytochrome P450 Enzymes Using a Simple In Vitro Inhibition Screen Drug Metab. Dispos., October 1, 1997; 25(10): 1211 - 1214. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Tomkins, S. V. Otton, N. Joharchi, N-Y. Li, R. F. Balster, R. F. Tyndale, and E. M. Sellers Effect of Cytochrome P450 2D1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1374 - 1382. [Abstract] [Full Text]
|
|
|
|
|
|
M. E. Fitzsimmons and J. M. Collins Selective Biotransformation of the Human Immunodeficiency Virus Protease Inhibitor Saquinavir by Human Small-Intestinal Cytochrome P4503A4. Potential Contribution to High First-Pass Metabolism Drug Metab. Dispos., February 1, 1997; 25(2): 256 - 266. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, K. Chiba, T. Yagi, N. Shimada, T. Taniguchi, T. Horie, M. Tani, T. Yamamoto, T. Ishizaki, and Y. Kuroiwa Identification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 927 - 933. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. P. Guengerich, A. D. N. Vaz, G. N. Raner, S. J. Pernecky, and M. J. Coon Evidence for a Role of a Perferryl-Oxygen Complex, FeO3+, in the N-Oxygenation of Amines by Cytochrome P450 Enzymes Mol. Pharmacol., January 1, 1997; 51(1): 147 - 151. [Abstract] [Full Text]
|
|
|
|
|
|
A. P. Koley, J. T. M. Buters, R. C. Robinson, A. Markowitz, and F. K. Friedman CO Binding Kinetics of Human Cytochrome P450 3A4 J. Biol. Chem., March 10, 1995; 270(10): 5014 - 5018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Straka and P. S. Marshall The Clinical Significance of the Pharmacogenetics of Cardiovascular Medications Journal of Pharmacy Practice, January 1, 1992; 5(6): 337 - 361. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
